Lung Cancer Diagnosis Breakthrough from superDimension Receives Category I(R) CPT Reimbursement Codes

Lung Cancer Diagnosis Breakthrough from superDimension Receives Category I(R)
CPT Reimbursement Codes
Company Expects Broadened Physician Adoption for Minimally Invasive Technology
That Offers Potential to Change Standard of Care

MINNEAPOLIS, Nov. 2 /PRNewswire/ -- superDimension, Inc.®, a private company
that develops minimally invasive interventional pulmonology devices, announced
today that The American Medical Association (AMA) has issued a new Category I
CPT® code for the use of the Company's electromagnetic navigational
bronchoscopy (ENB) device to navigate to lesions or spots deep in the lungs.
The code will become effective January 1, 2010. The AMA also issued a new CPT
I® code for the placement of fiducial radiosurgical markers via the ENB
procedure.

ENB is a minimally invasive procedure, where a catheter is inserted through
the throat or nose and uses Global Positioning System (GPS) like technology to
biopsy lung lesions and lymph nodes all in one outpatient procedure. ENB
provides a three-dimensional virtual "roadmap" of the lungs that enables a
physician to maneuver the catheters through multiple branches of the bronchial
tree, extending beyond the capabilities of the traditional bronchoscope to
distant, previously inaccessible regions of the lungs. If the targeted lesions
are determined to be cancerous, a pulmonologist can use ENB to
transbronchially place radiosurgical markers in and around lung tumors
(lesions) to help radiation oncologists treat patients with external beam
radiation. The outpatient procedure typically leaves the patient with no more
than a sore throat.

Previously, the "gold standard" to diagnose lung cancer consisted of two
invasive surgeries: wedge thoracotomy (open chest partial lung removal) to
biopsy the lung and mediastinoscopy (invasive lymph node surgery) to biopsy
the lymph nodes. Patients with poor lung function who could not tolerate
these more invasive procedures were left with "watchful waiting" as their only
option.

"ENB has completely transformed my medical practice and the way I diagnose and
facilitate the treatment of early stage lung cancer patients," said David
Wilson, M.D. at Columbus Regional Hospital in Columbus, Indiana. "If we can
diagnose and treat lung cancer in its early stages, we should be able to
dramatically increase the long-term survival rate for patients."

Dan Sullivan, president and chief executive officer, said, "Early diagnosis
and treatment are crucial for improving survival rates in lung cancer. The
prior standard of care left patients with the option of either undergoing
invasive procedures or watchful waiting for an increase in lesion (spot) size.
We believe ENB will revolutionize the way physicians and patients think about
the diagnosis of lung cancer. With the introduction of ENB, patients finally
gained a minimally invasive alternative for this early diagnosis."

Mr. Sullivan continued, "The establishment of a Category I CPT® code is a
major milestone for superDimension. We believe the new CPT code will enable
hospitals to more easily submit reimbursement for ENB procedures."

ENB has received FDA 510(k) clearance in the United States, CE Mark in Europe
and it has also been approved for use in Australia and Canada. ENB has been
performed on more than 9,000 patients in over 200 hospitals worldwide.

Separately, superDimension also debuted today the iLogic(TM) system, its next
generation ENB technology, at the American College of Chest Physicians (CHEST)
meeting in San Diego (booth number 819) and the American Society for Radiation
Oncology (ASTRO) Conference in Chicago (booth number 3216).

About Lung Cancer
According to the Centers for Disease Control (CDC), "Lung cancer is the
leading cause of cancer deaths in the United States, causing more deaths than
the next three deadliest cancers combined -- breast cancer, prostate cancer
and colon cancer. Each year, approximately 200,000 patients are newly
diagnosed with lung cancer in the United States and an additional 160,000
patients die from the disease." The company notes, this is in addition to the
millions of patients who are currently on watchful waiting with an undiagnosed
spot on their lung.

For more information about lung cancer and its diagnosis, please visit
www.spotonyourlung.com.

About superDimension
superDimension, Inc. is a Minneapolis-based, privately held company that
develops and markets catheter based devices for use in the minimally invasive
diagnosis and treatment of early stage lung cancer and other diseases, using
the patient's natural airways to avoid surgery. For more information, please
visit www.superdimension.com.

COMPANY CONTACTS: Media and Investor Contacts:
----------------- ----------------------------
superDimension, Inc. The Ruth Group
Dan Sullivan Scott Lerman (media)
President and CEO 646-536-7013
763-210-4011 slerman@theruthgroup.com

Rick Buchholz Nick Laudico (investors)
Chief Financial Officer 646-536-7030
763-210-4012 nlaudico@theruthgroup.com

SOURCE superDimension, Inc.

Dan Sullivan, President and CEO, +1-763-210-4011, or Rick Buchholz, Chief
Financial Officer, +1-763-210-4012, both of superDimension, Inc. or media,
Scott Lerman, +1-646-536-7013, slerman@theruthgroup.com, or investors, Nick
Laudico, +1-646-536-7030, nlaudico@theruthgroup.com